RecruitingNCT06550882

A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea

Studying Acquired hemophilia A

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Takeda
Principal Investigator: Study Director
Takeda
Intervention: OBIZUR(drug)
Enrollment: 9 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2026

Study locations (1)

Kyung Hee University Hospital at Gangdong, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06550882 on ClinicalTrials.gov

Other trials for Acquired hemophilia A

Additional recruiting or active studies for the same condition.

RECRUITINGNCT06461533
A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A
Takeda
ACTIVE NOT RECRUITINGPHASE2NCT05345197
Emicizumab in Patients With Acquired Hemophilia A
University of Washington

See all trials for Acquired hemophilia A →

← Back to all trials